x

Posted 03 October, 2023

Syneos Health, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:SYNH in a 8-K filed on 03 October, 2023.


  On October 3, 2023, Syneos Health, Inc. (the "Company") publicly announced that Colin Shannon has been appointed Chief Executive Officer of the Company, effective immediately.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Syneos Health, Inc.
Health Care/Life Sciences • Biotechnology
Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC.
Market Cap
N/A
View Company Details
Syneos Health, Inc. by TradingView
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. 


On October 3, 2023, Syneos Health, Inc. (the "Company") publicly announced that Colin Shannon has been appointed Chief Executive Officer of the Company, effective immediately. Mr. Shannon succeeds Michelle Keefe, who will continue her tenure with the Company as a key member of the Executive Leadership Team. Mr. Shannon and Ms. Keefe will remain on the Board of Directors of the Company. 

Mr. Shannon does not have any family relationships with any director or executive officer of the Company. In addition, there have been no transactions directly or indirectly involving Mr. Shannon that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended. 

A copy of the press release announcing the leadership change is attached hereto as Exhibit 99.1 and is incorporated herein by reference.